文献速递慢性肾脏病遗传性与小管间质肾病

非奈利酮加入RAS/SGLT2阻断治疗Alport综合征CKD:Col4a3-/-小鼠随机对照试验

Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice.
PubMed 文献 · J Am Soc Nephrol · 2023-07-10

在Col4a3缺陷Alport肾病小鼠中开展临床前随机对照试验,比较晚期加用非奈利酮的三联疗法与RAS/SGLT2双重阻断。三联组平均生存103.1±20.3天,显著长于双联组80.3±11.0天和雷米普利单药组77.3±5.3天。病理组学与RNA测序显示非奈利酮主要抑制残余小管间质炎症和纤维化。

要点

  • Col4a3-/-小鼠晚期启动三联RAS/SGLT2/MR阻断,平均生存103.1天,双联80.3天,单药77.3天。
  • 加用非奈利酮主要抑制双联阻断后残余的小管间质炎症和纤维化。
  • 作者认为三联阻断可能对Alport综合征及其他进展性CKD有协同肾脏保护作用。

核心结论

  • 小鼠实验提示三联RAS/SGLT2/MR阻断可能通过肾小球和小管间质的协同效应,显著改善Alport综合征及可能的其他进展性CKD的肾脏结局。

研究设计与样本

  • 临床前随机对照试验(PCTE0000266),在已建立Alport肾病的Col4a3缺陷小鼠中,于6周龄晚期启动治疗。
  • 40只雄性加40只雌性小鼠区组随机分配至溶媒、雷米普利单药(10 mg/kg)、雷米普利加恩格列净(30 mg/kg)双联、或雷米普利加恩格列净加非奈利酮(10 mg/kg)三联,均为饲料混入给药。
  • 主要终点为平均生存期。

主要发现

  • 平均生存期:溶媒组63.7±10.0天,雷米普利单药组77.3±5.3天,双联组80.3±11.0天,三联组103.1±20.3天。
  • 性别不影响结局。
  • 组织病理学、病理组学和RNA测序显示,在双联RAS/SGLT2阻断基础上加用非奈利酮主要抑制残余的小管间质炎症和纤维化。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SIGNIFICANCE STATEMENT: We hypothesized that triple therapy with inhibitors of the renin-angiotensin system (RAS), sodium-glucose transporter (SGLT)-2, and the mineralocorticoid receptor (MR) would be superior to dual RAS/SGLT2 blockade in attenuating CKD progression in Col4a3 -deficient mice, a model of Alport syndrome. Late-onset ramipril monotherapy or dual ramipril/empagliflozin therapy attenuated CKD and prolonged overall survival by 2 weeks. Adding the nonsteroidal MR antagonist finerenone extended survival by 4 weeks. Pathomics and RNA sequencing revealed significant protective effects on the tubulointerstitium when adding finerenone to RAS/SGLT2 inhibition. Thus, triple RAS/SGLT2/MR blockade has synergistic effects and might attenuate CKD progression in patients with Alport syndrome and possibly other progressive chronic kidney disorders. BACKGROUND: Dual inhibition of the renin-angiotensin system (RAS) plus sodium-glucose transporter (SGLT)-2 or the mineralocorticoid receptor (MR) demonstrated additive renoprotective effects in large clinical trials. We hypothesized that triple therapy with RAS/SGLT2/MR inhibitors would be superior to dual RAS/SGLT2 blockade in attenuating CKD progression. METHODS: We performed a preclinical randomized controlled trial (PCTE0000266) in Col4a3 -deficient mice with established Alport nephropathy. Treatment was initiated late (age 6 weeks) in mice with elevated serum creatinine and albuminuria and with glomerulosclerosis, interstitial fibrosis, and tubular atrophy. We block-randomized 40 male and 40 female mice to either nil (vehicle) or late-onset food admixes of ramipril monotherapy (10 mg/kg), ramipril plus empagliflozin (30 mg/kg), or ramipril plus empagliflozin plus finerenone (10 mg/kg). Primary end point was mean survival. RESULTS: Mean survival was 63.7±10.0 days (vehicle), 77.3±5.3 days (ramipril), 80.3±11.0 days (dual), and 103.1±20.3 days (triple). Sex did not affect outcome. Histopathology, pathomics, and RNA sequencing revealed that finerenone mainly suppressed the residual interstitial inflammation and fibrosis despite dual RAS/SGLT2 inhibition. CONCLUSION: Experiments in mice suggest that triple RAS/SGLT2/MR blockade may substantially improve renal outcomes in Alport syndrome and possibly other progressive CKDs because of synergistic effects on the glomerular and tubulointerstitial compartments.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Zhu Z, Rosenkranz KAT, Kusunoki Y, et al. Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice. J Am Soc Nephrol. 2023. PMID: 37428955. doi:10.1681/ASN.0000000000000186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。